[go: up one dir, main page]

WO2006117165A3 - Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire - Google Patents

Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire Download PDF

Info

Publication number
WO2006117165A3
WO2006117165A3 PCT/EP2006/004022 EP2006004022W WO2006117165A3 WO 2006117165 A3 WO2006117165 A3 WO 2006117165A3 EP 2006004022 W EP2006004022 W EP 2006004022W WO 2006117165 A3 WO2006117165 A3 WO 2006117165A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
stroke
methods
head injuries
saha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/004022
Other languages
English (en)
Other versions
WO2006117165A2 (fr
Inventor
Ingmar Bluemcke
Eric Hahnen
Florian Siebzehnruebl
Rolf Buslei
Ilker Yasin Eyuepoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Friedrich Alexander Universitaet Erlangen Nuernberg
Original Assignee
Friedrich Alexander Universitaet Erlangen Nuernberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Friedrich Alexander Universitaet Erlangen Nuernberg filed Critical Friedrich Alexander Universitaet Erlangen Nuernberg
Publication of WO2006117165A2 publication Critical patent/WO2006117165A2/fr
Publication of WO2006117165A3 publication Critical patent/WO2006117165A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs de HDAC pour la préparation d'une composition pharmaceutique permettant d'améliorer, de traiter ou de prévenir des malignités se rapportant à des événements ischémiques ou des lésions cérébrales. L'inhibiteur de HDAC est choisi dans le groupe constitué de SAHA, M344, MS-275, CBHA et SBHA, SAHA étant l'inhibiteur de HDAC préféré.
PCT/EP2006/004022 2005-05-02 2006-04-28 Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire Ceased WO2006117165A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPEP05009614 2005-05-02
EP05009614 2005-05-02

Publications (2)

Publication Number Publication Date
WO2006117165A2 WO2006117165A2 (fr) 2006-11-09
WO2006117165A3 true WO2006117165A3 (fr) 2007-04-26

Family

ID=36954780

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/004022 Ceased WO2006117165A2 (fr) 2005-05-02 2006-04-28 Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire

Country Status (1)

Country Link
WO (1) WO2006117165A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007130419A2 (fr) * 2006-05-04 2007-11-15 Merck & Co., Inc. Inhibiteurs de l'histone desacétylase pour le traitement de la neurodégénération
WO2008126932A2 (fr) * 2007-04-09 2008-10-23 Riken Régulation épigénétique de la plasticité du cerveau
WO2011143308A2 (fr) 2010-05-11 2011-11-17 The General Hospital Corporation Biomarqueurs du choc hémorragique
WO2012120262A1 (fr) * 2011-03-09 2012-09-13 Larsson Pia Composés et procédés d'amélioration d'une fibrinolyse endogène dysfonctionnelle à l'aide d'inhibiteurs d'histone désacétylase
TWI464147B (zh) * 2011-09-15 2014-12-11 Univ Taipei Medical 吲哚氫胺酸和吲哚啉氫胺酸於治療心臟衰竭或神經損傷的用途
US20160008336A1 (en) * 2013-03-05 2016-01-14 Lixte Biotechnology, Inc. Hdac inhibitors for the treatment of traumatic brain injury
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
CN114209667A (zh) 2016-04-08 2022-03-22 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032921A2 (fr) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Traitement des maladies neurodegeneratives et du cancer du cerveau

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003032921A2 (fr) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Traitement des maladies neurodegeneratives et du cancer du cerveau

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BLANCHARD F ET AL: "Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 10, no. 3, 1 February 2005 (2005-02-01), pages 197 - 204, XP004748155, ISSN: 1359-6446 *
CHUANG D-M: "Lithium protection from glutamate excitotoxicity: therapeutic implications", CLINICAL NEUROSCIENCE RESEARCH, ELSEVIER, LONDON, GB, vol. 4, no. 3-4, December 2004 (2004-12-01), pages 243 - 252, XP004732774, ISSN: 1566-2772 *
EYAL S ET AL: "The activity of antiepileptic drugs as histone deacetylase inhibitors", EPILEPSIA 2004 UNITED STATES, vol. 45, no. 7, 2004, pages 737 - 744, XP009048454, ISSN: 0013-9580 *
FARACO G ET AL: "Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain", MOLECULAR PHARMACOLOGY 2006 UNITED STATES, vol. 70, no. 6, 2006, pages 1876 - 1884, XP009077326, ISSN: 0026-895X 1521-0111 *
GLASER K B ET AL: "Differential protein acetylation induced by novel histone deacetylase inhibitors.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 17 DEC 2004, vol. 325, no. 3, 17 December 2004 (2004-12-17), pages 683 - 690, XP004635478, ISSN: 0006-291X *
JEONG M R ET AL: "Valproic acid, a mood stabilizer and anticonvulsant, protects rat cerebral cortical neurons from spontaneous cell death: a role of histone deacetylase inhibition", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 542, no. 1-3, 8 May 2003 (2003-05-08), pages 74 - 78, XP004422726, ISSN: 0014-5793 *
SUURONEN T ET AL: "Regulation of microglial inflammatory response by histone deacetylase inhibitors", JOURNAL OF NEUROCHEMISTRY 2003 UNITED KINGDOM, vol. 87, no. 2, 2003, pages 407 - 416, XP002415488, ISSN: 0022-3042 *

Also Published As

Publication number Publication date
WO2006117165A2 (fr) 2006-11-09

Similar Documents

Publication Publication Date Title
WO2007127158A3 (fr) Modification d'absorption percutanée de matériaux topiquement actifs
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2010032875A3 (fr) Composés de carboxamide hétérocycliques
ZA200806778B (en) N-Hydroxyacrylamide compounds
WO2011091213A3 (fr) Composés amide inverse en tant qu'inhibiteurs de protéine désacétylase et procédés d'utilisation associés
CL2007001882A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2008088030A1 (fr) Composition destinée à la prévention ou au traitement d'une maladie associée à un thrombus ou à un embole
WO2007077186A8 (fr) Inhibiteurs de pdf
EP2607348A3 (fr) Agent inhibiteur de l'inhibiteur de l'activateur du plasminogène 1
WO2007087431A3 (fr) Pulvérisation sublinguale de fentanyle
CL2007001881A1 (es) Compuestos derivados de imidazopirimidina; proceso para preparar los compuestos; composicion farmaceutica; y uso para la prevencion y/o tratamiento de desordenes cognitivos.
WO2008073138A3 (fr) Composés et compositions de téréphtalamate, et leur utilisation en tant qu'inhibiteurs de l'intégrase du vih
CL2007000918A1 (es) Compuestos derivados de enfumafungina, inhibidores de (1,3)-beta-d-glucanosintetasa; composicion farmaceutica; y uso para tratar una infeccion fungica.
González-Muñoz et al. N-acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer’s disease
WO2004103283A3 (fr) Compositions comprenant un inhibiteur selectif de cyclooxygenase-2 et un stimulant de systeme nerveux central pour le traitement d'une lesion du systeme nerveux central
WO2006117165A3 (fr) Moyens et procedes de traitement de lesions de la tete et d'accident cerebrovasculaire
WO2008104852A3 (fr) Compositions pharmaceutiques comprenant un adsorbate de fénofibrate
WO2011011420A3 (fr) Inhibiteurs 3, 4-méthylènedioxyphényle d'aminotransférase gaba et/ou de transporteur de recaptage de gaba
MX372773B (es) Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico.
WO2008055022A3 (fr) Procédés de traitement de la dépression
DK1954251T3 (da) Sammensætning med langvarig frigivelse, som har jernsalt som aktiv bestanddel, fremgangsmåde til fremstilling deraf og anvendelse deraf
WO2007044325A3 (fr) Inhibiteurs de l'interaction du domaine apoe4 et methodes d'utilisation
BRPI0516128A (pt) uso de inibidores de renina para a prevenção ou tratamento de disfunção diastólica ou insuficiência cardìca diastólica
WO2009148600A8 (fr) Composés à base de lysine deutérée
WO2010075086A3 (fr) Inhibiteurs de type pyrrolidinone de pde-4

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06724646

Country of ref document: EP

Kind code of ref document: A2